{"classes":[{"categories":[{"measurements":[{"comment":"No participants in this age group.","groupId":"OG000","spread":"NA","value":"NA"},{"comment":"No participants in this age group.","groupId":"OG001","spread":"NA","value":"NA"},{"comment":"No participants in this age group.","groupId":"OG002","spread":"NA","value":"NA"},{"comment":"Due to insufficient number of participants in this age group (only 1 participant), CV% could not be calculated.","groupId":"OG003","spread":"NA","value":"1.9"}]}],"title":"Infants and Toddlers (age<2yr; n=0; n=0; n=0; n=1)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"50.4","value":"8.8"},{"groupId":"OG001","spread":"145.2","value":"16.6"},{"groupId":"OG002","spread":"71.1","value":"25.4"},{"groupId":"OG003","spread":"102.2","value":"23.6"}]}],"title":"Children (age>=2 & <12yr; n=7; n=12; n=5; n=6)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"38.4","value":"12.3"},{"groupId":"OG001","spread":"54.4","value":"13.5"},{"groupId":"OG002","spread":"112.3","value":"20.0"},{"groupId":"OG003","spread":"105.5","value":"15.8"}]}],"title":"Adolescents (age>=12 & <12yr; n=6; n=8; n=9; n=2)"},{"categories":[{"measurements":[{"comment":"Due to insufficient number of participants in this age group (only 1 participant), CV% could not be calculated.","groupId":"OG000","spread":"NA","value":"NA"},{"comment":"Due to insufficient number of participants in this age group (only 1 participant), CV% could not be calculated.","groupId":"OG001","spread":"NA","value":"6.6"},{"comment":"No participants in this age group.","groupId":"OG002","spread":"NA","value":"NA"},{"comment":"No participants in this age group.","groupId":"OG003","spread":"NA","value":"NA"}]}],"title":"Above 18 years (n=0; n=1; n=0; n=0)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"44.9","value":"10.3"},{"groupId":"OG001","spread":"141.1","value":"14.7"},{"groupId":"OG002","spread":"100.1","value":"21.8"},{"groupId":"OG003","spread":"110.3","value":"16.3"}]}],"title":"Total"}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"21"},{"groupId":"OG002","value":"14"},{"groupId":"OG003","value":"9"}],"units":"Participants"}],"description":"PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. AUC(0-T) is the area under the plasma concentration-time curve from time zero to time of last quantifiable concentration.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Dasatinib 60 mg/m\\^2 QD, as long as clinical benefit was maintained.","id":"OG000","title":"Dasatinib 60 mg/m^2"},{"description":"Tablets, Oral; If necessary in participants who could not swallow, tablets were dispersed into 30 cc of 100% fruit juice with no preservatives (minute maid lemonade or orange juice or apple juice). Dasatinib 80 mg/m\\^2 QD, as long as clinical benefit was maintained.","id":"OG001","title":"Dasatinib 80 mg/m^2"},{"description":"Tablets, Oral; If necessary in participants who could not swallow, tablets were dispersed into 30 cc of 100% fruit juice with no preservatives (minute maid lemonade or orange juice or apple juice). Dasatinib 100 mg/m\\^2 QD, as long as clinical benefit was maintained.","id":"OG002","title":"Dasatinib 100 mg/m^2"},{"description":"Tablets, Oral; If necessary in participants who could not swallow, tablets were dispersed into 30 cc of 100% fruit juice with no preservatives (minute maid lemonade or orange juice or apple juice). Dasatinib 120 mg/m\\^2 QD, as long as clinical benefit was maintained.","id":"OG003","title":"Dasatinib 120 mg/m^2"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"All treated participants with plasma samples available. n=number of PK parameters included. Each participant could have more than 1 plasma profiles sampled, depending on the number of times the dose of dasatinib was escalated.","reportingStatus":"POSTED","timeFrame":"During Week 1 of Course 1, and any course in which dose escalation was performed (at pre-dose, and at 0.5, 1, 2, 4, 6, 8 and 24 hours).","title":"Dasatinib Metabolite (BMS-582691) Plasma Pharmacokinetic Parameter: Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUC[0-T]) by Dose Level and Age Group","type":"SECONDARY","unitOfMeasure":"ng.h/mL"}